Sulfamethoxazole


Concise Prescribing Info
Indications/Uses
Susceptible infections.
Dosage/Direction for Use
Adult : PO Initial: 2 g, then 1 g twice daily. Severe: 1 g 3 times/day.
Dosage Details
Oral
Urinary tract infections, Otitis media, Chlamydial infections, Prophylaxis of meningococcal meningitis
Adult: Initially, 2 g followed by 1 g bid. Severe infections: 1 g tid.
Child: Initially, 50-60 mg/kg, followed by 25-30 mg/kg bid. Max daily dose: 75mg/kg.
Renal Impairment
Dose reduction in renal impairment
Administration
Should be taken on an empty stomach.
Contraindications
Severe renal or hepatic impairment, blood disorders, hypersensitivity to sulfonamides, porphyria, SLE, infants <2 mth, pregnancy (3rd trimester) and lactation.
Special Precautions
Renal or hepatic impairment, history of allergy or asthma, AIDS, G6PD deficiency, elderly, ensure adequate fluid intake to reduce risk of crystalluria. Pregnancy.
Adverse Reactions
Nausea, vomiting, anorexia, diarrhoea, hypersensitivity reactions, blood disorders, serum sickness-like syndrome, hypoglycaemia, hypothyroidism, pseudomembranous colitis, kernicterus in premature neonates.
IV/Parenteral/PO: D
Drug Interactions
Concurrent use increases phenytoin and methotrexate levels; increased risk of bleeding with warfarin and acenocoumarol; may potentiate antidiabetic effect of sulphonylureas.
Potentially Fatal: Concurrent use increased risk of blood dyscrasias with clozapine and pyrimethamine.
Lab Interference
Interference with tests for urea, creatinine, urinary glucose, urobilinogen.
Action
Description: Sulfamethoxazole is an intermediate-acting sulfonamide which interferes with the synthesis of nucleic acids in sensitive organisms by blocking the conversion of PABA to the coenzyme dihydrofolic acid. Its action is bacteriostatic, although it can be bactericidal where concentrations of thymine are low in the surrounding medium. It has broad spectrum of action though its usefulness has been greatly reduced by widespread resistance.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Sulfamethoxazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in